Click on headlines below to download research

Feraccru performs again in a Phase III study
Shield Therapeutics | 04/03/2019

Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-approved oral formulation of iron positioned…

Fortified for growth
Shield Therapeutics | 19/02/2019

Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment…